PCOS phenotypes are variably associated with pregnancy complications. We aimed to conduct a meta-analysis of pregnancy complications in women with and without PCOS by PCOS phenotypes.
Background: Transitional neonatal hypoglycaemia is common and usually resolves within 48 h. However, some babies experience persistent hypoglycaemia, which has not been well described.
Methods: Cases were defined as: >35 weeks; ≥1 hypoglycaemic episode <72 and ≥72 h; treatment for ≥72 h; excluded if congenital metabolic/endocrine disorders, malformations, HIE, confirmed sepsis. Hospital coding, laboratory and pharmacy databases were searched at two Auckland tertiary hospitals from January 2012 to December 2016. Records (including childhood) of all babies ≥72 h old with ICD10-P70 codes (Transitory disorders of carbohydrate metabolism), insulin measurement or diazoxide prescription were reviewed. Data were extracted onto prespecified forms.
Results: From 471 records screened, 39 met the case definition. Most were male (72%,28), Pacific (49%,19) or M aori (18%,7), small for gestational age (62%,24) and born by emergency caesarean (59%,23); only 5% (2) were large for gestational age. Median (IQR) birthweight z-score was −1.46 (−1.81,−0.97). Maternal diabetes was present in 18% (7), but no mother had a previous affected baby. In 82% (32), severe hypoglycaemia (<2 mM) occurred within 6h of birth. Cases required significant intervention, including: central lines (56%, 22), continuous feeding (26%,10), medications for hypoglycaemia (18%,7), formula feeds (85%, 33), and respiratory support (46%,18). Median(IQR) duration (days) were: admission 12 (10,15), central line 5 (5,8), intravenous fluids 6 (5,7), nasogastric feeding 9(8,14). Maximum glucose delivery rate was 10 (5,8) mg/kg/min. Median (IQR) insulin concentration was 9(4,12) mU/L. Ketones were undetectable in 17/21(81%). Three of 4 babies with brain MRI had ischaemic/white matter changes.
Conclusions: Growth restricted babies with early severe hypoglycaemia are at risk of delayed metabolic transition and may warrant adjunctive therapy.
BPD OUTCOME ESTIMATOR: APPLICABILITY IN PRETERM INFANTS 2018
Baker EK Preventing bronchopulmonary dysplasia (BPD) is a research priority. However, predicting infants at greatest risk, those most suitable in which to study preventative therapies, is challenging. In a contemporary population, we evaluated an online 'BPD outcome estimator', developed based on data collected in 2002 for the NICHD Neonatal Research Network (Am J Respir Crit Care Med, 2011; 183(12):1715-22) .
Methods: This retrospective study included infants born <29 weeks' gestational age (GA), birthweight (BW) 501-1250 g from October 2016 to September 2017 admitted to Monash Newborn and The Royal Women's Hospital. The probability of death or BPD calculated by the 'BPD outcome estimator' on postnatal days 1, 3, 7,14, 21 and 28, was compared, using receiver operating characteristic (ROC) analysis, to the infants' outcome at 36 weeks' post menstrual age. Inputs for the estimator had to be adapted for ethnicity and use of high flow therapy.
Results: 184 infants were included. The incidence of severe BPD or death was 46.2% compared with 25.9% in the NICHD population. The areas under the curve (AUC) for each outcome/-postnatal day are reported below. However, the BPD estimator underestimated the risk of poor outcomes in our study population.
Conclusions: The BPD outcome estimator accurately models BPD risk based on AUC. However the estimates of poor outcome need recalibrating for an Australian population with a higher rate of BPD.
